Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Iolanda Donatella Vincelli et al.|Blood|2015Cited by 215
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemiaDavide Rossi, Marco Ladetto, Chiara Lobetti Bodoni et al.|Leukemia|2009Cited by 98
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaAlessandra Larocca, Antonio Palumbo, Sara Bringhen et al.|Leukemia|2016Cited by 46
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) PatientsSara Bringhen, Mario Boccadoro, Valeria Magarotto et al.|Blood|2016Cited by 7
Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II StudyAntonio Palumbo, Paolo Corradini, Davide Rossi et al.|Blood|2014Cited by 6